Antibiotic resistance in hospitals: A ward-specific random effect model in a low antibiotic consumption environment

Statistics in Medicine

Volumn 32, Issue 8, 2013, Pages 1407-1418

  Aldrin, Magne ^a   Raastad, Ragnhild ^b,c   Tvete, Ingunn Fride ^a   Berild, Dag ^b,c   Frigessi, Arnoldo ^a,c   Leegaard, Truls ^d   Monnet, Dominique L ^e   Walberg, Mette ^f   Müller, Fredrik ^b,c  

^a NORWEGIAN COMPUTING CENTER   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^f Vestre Viken Hospital Trust   (Norway)

Author keywords

Antibiotics; Binomial regression; Poisson regression; Resistance; Scenario analysis

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; IMIPENEM; MECILLINAM; MEROPENEM; PIVAMPICILLIN; PIVMECILLINAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; BINOMIAL DISTRIBUTION; DATA ANALYSIS; DRUG USE; ENVIRONMENTAL FACTOR; HEALTH STATISTICS; HUMAN; INCIDENCE; NONHUMAN; NORWAY; POISSON DISTRIBUTION; PSEUDOMONAS AERUGINOSA; PUBLIC HEALTH; RANDOM SAMPLE; RETROSPECTIVE STUDY; SAMPLE SIZE; SIMULATION; STATISTICAL MODEL;

ANTI-BACTERIAL AGENTS; COMPUTER SIMULATION; DRUG RESISTANCE, BACTERIAL; HOSPITALS; HUMANS; MODELS, STATISTICAL; NORWAY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 84875240528     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5636     Document Type: Article

References (38)

1. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrobial Agents and Chemotherapy 2008; 52:813-821. DOI: 10.1128/AAC.01169-07.
2. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Eurosurveillance 2008; 13(47):584-594.
3. Lepape A, Monnet DL. Experience of European intensive care physicians with infections due to antibiotic-resistant bacteria. Euro Surveillance 2009; 14(45):659-661.
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! an update from the infectious diseases society of America. Clinical Infectious Diseases 2009; 48:1-12. DOI: 10.1086/595011.
5. Lagamayo EN. Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries. American Journal of Infection Control 2008; 36(Suppl 4):S101-S108. DOI: 10.1016/j.ajic.2007.10.020.
6. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infectious Diseases 2010; 10:597-602. DOI: 10.1016/S1473-3099(10)70143-2.
7. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nature Reviews Microbiology 2010; 8:260-271. DOI: 10.1038/nrmicro2319.
8. Johnsen PJ, Townsend JP, Bohn T, Simonsen GS, Sundsfjord A, Nielsen KM. Factors affecting the reversal of antimicrobial-drug resistance. [Review] The Lancet Infectious Diseases 2009; 9:357-364. DOI: 10.1016/S1473-3099(09)70105-7.
9. Sundqvist M, Geli P, Andersson DI, Sjölund-Karlsson M, Runehagen A, Cars H, Abelson-Storby K, Cars O, Kahlmeter G. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. Journal of Antimicrobial Chemotherapy 2010; 65:350-360. DOI: 10.1093/jac/dkp387.
10. Bronzwaer SL, Cars O, Buchholz U, Mölstad S, Goettsch W, Veldhuijzen IK, Kool JL, Sprenger MJW, Degener JE. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerging Infectious Diseases 2002; 8:278-282.
11. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-587. DOI: 10.1016/S0140-6736(05)17907-0.
12. McGowan JE Jr. Is antimicrobial resistance in hospital microorganisms related to antibiotic use? Bulletin of the New York Academy of Medicine 1987; 63:253-268.
13. Box GEP, Jenkins GM. Time Series Analysis: Forecasting and Control, (2nd edn). Holden-Day: San Francisco, 1976.
14. López-Lozano JM, Monnet DL, Yagüe A, Burgos A, Gonzalo N, Campillos P, Saez M. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. International Journal of Antimicrobial Agents 2000; 14:21-31.
15. Monnet DL, MacKenzie FM, López-Lozano JM, Beyaert A, Camacho M, Wilson R, Stuart D, Gould IM. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerging Infectious Diseases 2004; 10:1432-1441.
16. Muller AA, Mauny F, Bertin M, Cornette C, López-Lozano JM, Viel JF, Talon DR, Bertrand X. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clinical Infectious Diseases 2003; 36:971-978.
17. Aldeyab MA, Monnet DL, López-Lozano JM, Hughes CM, Scott MG, Kearney MP, Magee FA, McElnay JC. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. Journal of Antimicrobial Chemotherapy 2008; 62:593-600. DOI: 10.1093/jac/dkn198.
18. Vernaz N, Sax H, Pittet D, Bonnabry P, Schrenzel J, Harbarth S. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. Journal of Antimicrobial Chemotherapy 2008; 62:601-607. DOI: 10.1093/jac/dkn199.
19. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), ECDC, Stockholm.
20. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H, ESAC Project Group. Hospital consumption of antibiotics in 15 European countries: results of the ESAC Retrospective Data Collection (1997-2002). Journal of Antimicrobial Chemotherapy 2006; 58:159-167.
21. NORM/NORM-VET 2009. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Troms/Oslo, 2010. ISSN:1502-2307 (print) / 1890-9965 (electronic).
22. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clinical Infectious Diseases 2003; 36(Suppl 1):S11-S23.
23. Berhane K, Thomas DC. A two-stage model for multiple time series data of counts. Biostatistics 2002; 3:21-32.
24. Schwarz G. Estimating the dimension of a model. The Annals of Statistics 1978; 6:461-464.
25. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare Clinical Infectious Diseases 2002; 34:634-640.
26. Zavascki AP, Cruz RP, Goldani LZ. High rate of antimicrobial resistance in Pseudomonas aeruginosa at a tertiary-care teaching hospital in southern Brazil. Infection Control and Hospital Epidemiology 2004; 25:805-807. DOI: 10.1093/jac/dki390.
27. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infection Control and Hospital Epidemiology 2010; 31:47-53. DOI: 10.1086/649021.
28. Erdeljic V, Francetic I, Bosnjak Z, Budimir A, Kalenic S, Bielen L, Makar-Ausperger K, Likic R. Distributed lags time series analysis versus linear correlation analysis (Pearson's r) in identifying the relationship between antipseudomonal antibiotic consumption and the susceptibility of Pseudomonas aeruginosa isolates in a single Intensive Care Unit of a tertiary hospital. International Journal of Antimicrobial Agents 2011; 37:467-471. DOI: 10.1016/j.ijantimicag.2010.11.030.
29. Hocquet D, Muller A, Blanc K, Plesiat P, Talon D, Monnet DL, Bertrand X. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2008; 52:1173-1175. DOI: 10.1128/AAC.01212-07.
30. Alcala-Franco B, Montanari S, Cigana C, Bertoni G, Oliver A, Bragonzi A. Antibiotic pressure compensates the biological cost associated with Pseudomonas aeruginosa hypermutable phenotypes in vitro and in a murine model of chronic airways infection. Journal of Antimicrobial Chemotherapy 2012; 67:962-969. DOI: 10.1093/jac/dkr587.
31. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Archives of Internal Medicine 1999; 159:1127-1132.
32. WHO Collaborating Center for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2011. Oslo, 2010. (Available from http://www.whocc.no/atc_ddd_publications/guidelines/. [Accessed on 24 September 2012].
33. WHONET 5.4. Software for the management and analysis of microbiology laboratory results. [computer program]. (Available from http://www.who.int/drugresistance/whonetsoftware/en/. [Accessed on 11 May 2011]).
34. Stelling JM, O'Brien TF. Surveillance of antimicrobial resistance: the WHONET program. Clinical Infectious Diseases 1997; 24(Suppl 1):S157-S168.
35. Claeskens G, Hjort NL. Model Selection and Model Averaging. Cambridge University Press: Cambridge, 2008.
36. Broström G. Package glmmML. (Available from http://cran.r-project.org/web/packages/glmmML/glmmML.pdf. [Accessed on 24 September 2012]), 2009; 1-14.
37. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrobial Agents and Chemotherapy 1999; 43:1379-1382.
38. Lepper PM, Grusa E, Reichl H, Högel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2002; 46:2920-2925.